Ticagrelor Tablet, Film Coated
Product Images NDC 69097-989

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 69097-989). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

60mg 100 Count. (60mg 100 Count)

60mg 100 Count. (60mg 100 Count)
The text provides information about Ticagrelor tablets, each containing 60mg of Ticagrelor. It includes dosage instructions, storage recommendations, and caution to keep the medication out of reach of children. The medication guide must be dispensed separately to each patient. It also mentions the manufacturer as InvaGen Pharmaceuticals, Inc., and the distributing company as Cipla USA, Inc.*
FDA Label Image

60mg 500 Count. (60mg 500 Count)

60mg 500 Count. (60mg 500 Count)
This text is a prescription label for Ticagrelor tablets, containing 60mg per tablet. The label instructs the pharmacist to dispense the Medication Guide separately to each patient. It indicates that there are 500 tablets in the container and provides storage instructions between 20-25°C (68-77°F). The pharmacist should dispense the tablets in a tight container with a child-resistant closure. The manufacturer is InvaGen Pharmaceuticals, Inc., and the tablets were manufactured for Cipla USA, Inc. The label also includes a warning to keep the medication out of the reach of children. Additionally, it references a package insert for full prescribing information and provides a revision date of 03/2025.*
FDA Label Image

60mg 60 Count. (60mg 60 Count)

60mg 60 Count. (60mg 60 Count)
Description: This text is information related to a pharmaceutical product with NDC code 69097-989-03 containing 60 mg of tigagrelor in film-coated tablets. It provides storage instructions, dosage details, and warnings. The medication should be dispensed in a tightly closed container. It advises pharmacists to dispense the medication guide with care and provides contact information for the manufacturer, Cipla USA, Inc.*
FDA Label Image

90mg 100 Count. (90mg 100 Count)

90mg 100 Count. (90mg 100 Count)
This is a prescription-only medication called Ticagrelor in tablet form. Each film-coated tablet contains 90 mg of Ticagrelor. The usual dosage should be followed as per the package insert for full prescribing information. The medication should be stored at a temperature between 20° to 25°C (68° to 77°F) with permitted excursions to 15° to 30°C (59° to 86°F). It is important to keep the medication tightly closed and out of reach of children. The Ticagrelor tablets are manufactured by InvaGen Pharmaceuticals and distributed by Cipla USA.*
FDA Label Image

90mg 500 Count. (90mg 500 Count)

90mg 500 Count. (90mg 500 Count)
This text is providing information about Ticagrelor tablets with NDC 59097-991. It includes details on the quantity of tablets, the dosage, storage instructions, manufacturer information, and warnings about keeping the medication away from children. The text recommends dispensing the tablets in a tight container and references the USP controlled room temperature requirements. It also mentions the package insert for full prescribing information.*
FDA Label Image

90mg 60 Tablets. (90mg 60 Tablets)

90mg 60 Tablets. (90mg 60 Tablets)
The text provides information on Ticagrelor, a medication in the form of tablets. It includes details on the dosage, storage instructions, manufacturer, and a warning about keeping it out of reach of children. The tablets contain 90 mg of Ticagrelor. The medication should be dispensed in a light-resistant container as per USP requirements. For full prescribing information, refer to the package insert.*
FDA Label Image

Fig 10. (Fig 10)

Fig 10. (Fig 10)
This is a statistical evaluation of the effectiveness of two medications, Ticomg and Clopidogrel, in patients with events after randomization. The data includes the number of patients with events, Kaplan-Meier percentages at 12 months, hazard ratios, and p-values. The results suggest that Ticomg may have a lower risk compared to Clopidogrel. The analysis is displayed over a span of 360 days from randomization.*
FDA Label Image

Fig_1 (Fig 1)

Fig_1 (Fig 1)
This is a dataset showing the number and percentage of patents with various attributes at different time points from the first study drug dose. The text mentions the "Cumulative %" and details the ratios for different categories of patents. The data presents information on the number of patents belonging to different groups and the corresponding percentage values. It also includes the number of days from the first drug dose and specifies the risk level associated with different drug dosages.*
FDA Label Image

Fig_11. (Fig 11)

Fig_11. (Fig 11)
FDA Label Image

Fig_12. (Fig 12)

Fig_12. (Fig 12)
This description is not-available.*
FDA Label Image

Fig_13. (Fig 13)

Fig_13. (Fig 13)
Not available.*
FDA Label Image

Fig_14. (Fig 14)

Fig_14. (Fig 14)
FDA Label Image

Fig_15. (Fig 15)

Fig_15. (Fig 15)
FDA Label Image

Fig_16. (Fig 16)

Fig_16. (Fig 16)
FDA Label Image

Fig_17. (Fig 17)

Fig_17. (Fig 17)
FDA Label Image

Fig_18. (Fig 18)

Fig_18. (Fig 18)
FDA Label Image

Fig_2. (Fig 2)

Fig_2. (Fig 2)
FDA Label Image

Fig_3. (Fig 3)

Fig_3. (Fig 3)
This is a Cumulative percentage graph showing the events for Ticagrelor and Placebo over a period of 36 months from randomization. The data indicates a decreasing trend for events over time for both treatments as shown by the decreasing percentages. These results suggest a potential effect of the treatments on reducing the occurrence of events.*
FDA Label Image

Fig_4. (Fig 4)

Fig_4. (Fig 4)
This text contains data related to the percentage of participants in a study who received different treatments (placebo and a specific intervention), as well as the number of days from randomization and further information about the study groups.*
FDA Label Image

Fig_5. (Fig 5)

Fig_5. (Fig 5)
FDA Label Image

Fig_6. (Fig 6)

Fig_6. (Fig 6)
FDA Label Image

Fig_7. (Fig 7)

Fig_7. (Fig 7)
FDA Label Image

Fig_8. (Fig 8)

Fig_8. (Fig 8)
This text provides information on the mean effect and 90% confidence interval related to drug interactions with Ticagrelor. It lists recommendations for interacting drugs, such as strong CYP3A4 inhibitors like Ketoconazole and their dosing adjustments, moderate CYP3A4 inhibitors like Diltiazem, potent CYP3A4 inducers like Rifampin, and other medications like Aspirin, Desmopressin, Heparin, Enoraparin, and others. It also mentions the interaction with P-glycoprotein and CYP3A inhibitors like Cyclosporine and Morphine. Additional details are provided on recommended dosages and potential adjustments for various medications.*
FDA Label Image

Fig_9. (Fig 9)

Fig_9. (Fig 9)
This document provides information on drug interactions with Ticagrelor, a medication used to prevent blood clots. It includes recommendations on dosage adjustments for Ticagrelor when taken with other drugs such as Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. The text also mentions specific doses and whether there is a need for adjustment when combining Ticagrelor with the mentioned drugs.*
FDA Label Image

Structure. (Structure)

Structure. (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.